Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (211-220 of 306) with videos related to

Pageof 31
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 23, 2012
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral loadYasuji Arase, Yusuke Kawamura, Yoshiyuki Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2020
Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearanceFumitaka Suzuki, Tetsuya Hosaka, Masayasu Imaizumi, et al.
Journal of Medical Virology|March 22, 2005
Persistence of acute infection with hepatitis B virus genotype A and treatment in JapanYoshiyuki Suzuki, Mariko Kobayashi, Kenji Ikeda, et al.
Journal of Medical Virology|October 14, 2003
Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapyNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|June 11, 2019
Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing AnalysisTomoya Sano, Norio Akuta, Fumitaka Suzuki, et al.
Internal Medicine (Tokyo, Japan)|October 4, 2011
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patientsYasuji Arase, Yoshiyuki Suzuki, Fumitaka Suzuki, et al.
Journal of Medical Virology|January 19, 2006
Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutantsFumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, et al.
Journal of Medical Virology|September 25, 2008
Change of hepatitis B virus genotypes in acute and chronic infections in JapanMariko Kobayashi, Kenji Ikeda, Yasuji Arase, et al.
Intervirology|July 19, 2005
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapyNorio Akuta, Fumitaka Suzuki, Hitomi Sezaki, et al.
Journal of Gastroenterology and Hepatology|June 16, 2010
Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patientsFumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, et al.
Pageof 31

Showing results (211-220 of 306) with videos related to

Sort By:
Pageof 31
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 23, 2012
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral loadYasuji Arase, Yusuke Kawamura, Yoshiyuki Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2020
Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearanceFumitaka Suzuki, Tetsuya Hosaka, Masayasu Imaizumi, et al.
Journal of Medical Virology|March 22, 2005
Persistence of acute infection with hepatitis B virus genotype A and treatment in JapanYoshiyuki Suzuki, Mariko Kobayashi, Kenji Ikeda, et al.
Journal of Medical Virology|October 14, 2003
Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapyNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|June 11, 2019
Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing AnalysisTomoya Sano, Norio Akuta, Fumitaka Suzuki, et al.
Internal Medicine (Tokyo, Japan)|October 4, 2011
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patientsYasuji Arase, Yoshiyuki Suzuki, Fumitaka Suzuki, et al.
Journal of Medical Virology|January 19, 2006
Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutantsFumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, et al.
Journal of Medical Virology|September 25, 2008
Change of hepatitis B virus genotypes in acute and chronic infections in JapanMariko Kobayashi, Kenji Ikeda, Yasuji Arase, et al.
Intervirology|July 19, 2005
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapyNorio Akuta, Fumitaka Suzuki, Hitomi Sezaki, et al.
Journal of Gastroenterology and Hepatology|June 16, 2010
Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patientsFumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, et al.
Pageof 31